CN105473151B - 用于减少钾和治疗慢性肾病和/或慢性心脏病的微孔硅酸锆和利尿药 - Google Patents

用于减少钾和治疗慢性肾病和/或慢性心脏病的微孔硅酸锆和利尿药 Download PDF

Info

Publication number
CN105473151B
CN105473151B CN201480032064.8A CN201480032064A CN105473151B CN 105473151 B CN105473151 B CN 105473151B CN 201480032064 A CN201480032064 A CN 201480032064A CN 105473151 B CN105473151 B CN 105473151B
Authority
CN
China
Prior art keywords
value
ion
use according
less
potassium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480032064.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105473151A (zh
Inventor
D·J·凯泽
A·F·古伊勒姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zs Drugmaker
Original Assignee
Zs Drugmaker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51654632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105473151(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zs Drugmaker filed Critical Zs Drugmaker
Publication of CN105473151A publication Critical patent/CN105473151A/zh
Application granted granted Critical
Publication of CN105473151B publication Critical patent/CN105473151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480032064.8A 2013-04-05 2014-04-03 用于减少钾和治疗慢性肾病和/或慢性心脏病的微孔硅酸锆和利尿药 Active CN105473151B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361808897P 2013-04-05 2013-04-05
US61/808,897 2013-04-05
US201361914362P 2013-12-10 2013-12-10
US61/914,362 2013-12-10
US201461930331P 2014-01-22 2014-01-22
US61/930,331 2014-01-22
PCT/US2014/032815 WO2014165670A1 (en) 2013-04-05 2014-04-03 Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

Publications (2)

Publication Number Publication Date
CN105473151A CN105473151A (zh) 2016-04-06
CN105473151B true CN105473151B (zh) 2018-09-18

Family

ID=51654632

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480032064.8A Active CN105473151B (zh) 2013-04-05 2014-04-03 用于减少钾和治疗慢性肾病和/或慢性心脏病的微孔硅酸锆和利尿药

Country Status (21)

Country Link
US (3) US20140302175A1 (enExample)
EP (1) EP2981272B1 (enExample)
JP (1) JP6280636B2 (enExample)
KR (1) KR102308673B1 (enExample)
CN (1) CN105473151B (enExample)
AU (1) AU2014248081B2 (enExample)
BR (1) BR112015025438B1 (enExample)
CA (1) CA2908641C (enExample)
CL (1) CL2015002951A1 (enExample)
DK (1) DK2981272T3 (enExample)
ES (1) ES2943007T3 (enExample)
FI (1) FI2981272T3 (enExample)
HU (1) HUE061862T2 (enExample)
IL (1) IL241926B (enExample)
MX (1) MX2015014055A (enExample)
PH (1) PH12015502301A1 (enExample)
PL (1) PL2981272T3 (enExample)
PT (1) PT2981272T (enExample)
TW (1) TW201521746A (enExample)
WO (1) WO2014165670A1 (enExample)
ZA (1) ZA201507666B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900037T1 (it) 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
CN114917247B (zh) * 2022-05-18 2024-01-26 广东省疾病预防控制中心 纳米二氧化钛在防治肾损伤中的应用
CN117776193A (zh) * 2023-12-25 2024-03-29 杭州国瑞生物科技有限公司 一种环硅酸锆钠zs-9的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105895A1 (en) * 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20120213847A1 (en) * 2011-02-11 2012-08-23 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601398D0 (en) * 1996-01-24 1996-03-27 Piper Edwina M Composition
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
EP1307270A1 (en) * 2000-07-12 2003-05-07 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US6579460B1 (en) * 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
CN103919792B (zh) 2008-08-22 2018-03-09 瑞立普萨公司 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
MX2015000381A (es) * 2012-07-11 2015-11-23 Zs Pharma Inc Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia.
KR102184602B1 (ko) * 2012-10-22 2020-11-30 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 지르코늄 실리케이트

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105895A1 (en) * 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20120213847A1 (en) * 2011-02-11 2012-08-23 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACEI在糖尿病的临床应用;石福彦;《药品评价》;20081231;第5卷(第8期);第347-350页 *
肾素-血管紧张素系统阻断剂在慢性肾病治疗中的应用;陈颖颖，丁峰;《上海医药》;20130131;第34卷(第1期);第5-9页 *

Also Published As

Publication number Publication date
JP6280636B2 (ja) 2018-02-14
CA2908641C (en) 2022-10-18
EP2981272A1 (en) 2016-02-10
IL241926B (en) 2020-10-29
AU2014248081B2 (en) 2019-02-28
MX2015014055A (es) 2015-12-15
CL2015002951A1 (es) 2016-11-11
FI2981272T3 (fi) 2023-05-03
HUE061862T2 (hu) 2023-08-28
EP2981272A4 (en) 2016-12-07
WO2014165670A1 (en) 2014-10-09
EP2981272B1 (en) 2023-03-01
KR20150140750A (ko) 2015-12-16
US20140302175A1 (en) 2014-10-09
DK2981272T3 (da) 2023-05-01
US10695366B2 (en) 2020-06-30
BR112015025438B1 (pt) 2022-06-07
JP2016515624A (ja) 2016-05-30
HK1221177A1 (en) 2017-05-26
AU2014248081A1 (en) 2015-11-12
PH12015502301A1 (en) 2016-02-10
US20180271902A1 (en) 2018-09-27
ES2943007T3 (es) 2023-06-08
KR102308673B1 (ko) 2021-10-01
CN105473151A (zh) 2016-04-06
CA2908641A1 (en) 2014-10-09
PL2981272T3 (pl) 2023-05-29
ZA201507666B (en) 2019-09-25
PT2981272T (pt) 2023-05-03
BR112015025438A2 (pt) 2017-07-18
TW201521746A (zh) 2015-06-16
US20160051584A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
CN104797263B (zh) 用于治疗高钾血症的微孔硅酸锆
CN106170283B (zh) 用于治疗高钾血症的微孔硅酸锆
US20160271174A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
US10695366B2 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
US20150359821A1 (en) Microporous Zirconium Silicate for the Treatment of Hyperkalemia
HK40112785A (en) Microporous zirconium silicate for the treatment of hyperkalemia
KR20160096178A (ko) 리튬 공동 투여 없이 고칼륨혈증을 치료하기 위한 규산지르코늄
HK1231745A1 (zh) 用於治疗高钾血症的微孔硅酸锆
HK1221177B (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
HK1231745B (zh) 用於治疗高钾血症的微孔硅酸锆

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant